Skip to main content
Clinical Trials/NCT02122705
NCT02122705CompletedNot Applicable

A Case Series of Vital Signs-controlled, Patient Assisted Intravenous Analgesia (VPIA) Using Remifentanil for Labour and Delivery

KK Women's and Children's Hospital1 site in 1 country29 target enrollmentStarted: May 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
29
Locations
1
Primary Endpoint
Pain score

Study Overview

Brief Summary

This study is a prospective case series aiming to evaluate a new VPIA remifentanil algorithm which would benefit labouring mothers who are unable or unwilling to receive epidural analgesia.

Detailed Description

This study proposes a novel Vital signs-controlled, patient-assisted intravenous analgesia (VPIA) regimen that will enhance the efficacy, safety and personalization of remifentanil therapy for labouring women. This system will study the parturient's pattern of analgesic use in 15 min epochs and titrate the demand doses and basal infusion rate to maintain a plasma level of remifentanil that is appropriate for the degree of pain felt.

The system incorporates vital signs (pulse oximetry and heart rate values) into the algorithm which would temporarily stop the pumps and step down doses accordingly when predefined critical values are reached.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients who choose to use parenteral opioid for pain relief with informed consent
  • Patients who refuse labour epidural analgesia
  • Patients with contraindication to epidural analgesia (eg. Thrombocytopaenia, previous thoraco-lumbar spinal instrumentation)

Exclusion Criteria

  • Patients who are unable to understand instructions given regarding the use of patient controlled analgesia (PCA) or unable to self administer PCA boluses
  • Patients with difficulty in communication due to language differences
  • Patients with known hypersensitivity to remifentanil or any component of its formulation or to other fentanyl analogs
  • Patients with severe respiratory disease
  • Patients with history of drug dependence of recreational drug abuse
  • Patients with unmanaged foetal bradycardia

Outcomes

Primary Outcomes

Pain score

Time Frame: Duration of labour

Hourly maternal pain scores

Secondary Outcomes

  • Maternal outcomes(Duration of labour and one day post delivery)
  • Maternal side effects(Duration of labour and 1st day post delivery)
  • Remifentanil drug consumption(Duration of labour)

Investigators

Sponsor
KK Women's and Children's Hospital
Sponsor Class
Other Gov
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials